<DOC>
	<DOCNO>NCT02024152</DOCNO>
	<brief_summary>This study investigate pharmacokinetics ( PK ) together safety tolerability JDP-205 5 mg 10 mg intravenous dose 10 mg intramuscular dose , comparison market cetirizine oral product ZyrtecÂ® 10 mg tablet ( OTC product ) healthy male female volunteer single dose administration .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Trial JDP-205 Injection 10 mg</brief_title>
	<detailed_description />
	<mesh_term>Urticaria</mesh_term>
	<criteria>1 . Male female volunteer 2 . Volunteer age least 18 year 3 . Volunteer body mass index ( BMI ) great equal 18.50 30.00 kg/m2 4 . Non exsmokers ; exsmoker define someone completely stop smoke least 12 month day 1 study . 5 . Availability entire study period 6 . Motivated volunteer absence intellectual problem likely limit validity consent participate study compliance protocol requirement ; ability cooperate adequately ; ability understand observe instruction physician designee 7 . Clinical laboratory value within laboratory 's state normal range ; within range , must without clinical significance 8 . Have clinically significant disease capture medical history evidence clinically significant finding physical examination ( include examination anterolateral thigh muscle ) and/or clinical laboratory evaluation ( hematology , biochemistry , ECG urinalysis ) 9 . Willingness adhere protocol requirement evidence informed consent form ( ICF ) duly read , sign date volunteer 1 . Females pregnant lactate 2 . Females childbearing potential refuse use acceptable contraceptive regimen throughout entire duration study ( screen visit study completion ) 3 . History significant hypersensitivity cetirizine relate product ( include excipients formulation ) well severe hypersensitivity reaction ( like angioedema ) drug 4 . Presence significant gastrointestinal , liver kidney disease , condition know interfere absorption , distribution , metabolism excretion drug know potentiate predispose undesired effect 5 . History significant gastrointestinal , liver kidney disease may affect drug bioavailability 6 . Presence significant cardiovascular , pulmonary , hematologic , neurological , psychiatric , endocrine , immunologic dermatologic disease 7 . Suicidal tendency , history disposition seizure , state confusion , clinically relevant psychiatric disease 8 . Presence outofrange cardiac interval ( PR &lt; 110 msec , PR &gt; 200 msec , QRS &lt; 60 msec , QRS &gt; 110 msec QTc &gt; 440 msec ) screen ECG clinically significant ECG abnormalities 9 . Known presence rare hereditary problem galactose /or lactose intolerance 10 . Maintenance therapy drug , significant history drug dependency alcohol abuse ( &gt; 3 unit alcohol per day , intake excessive alcohol , acute chronic ) 11 . Any clinically significant illness previous 28 day day 1 study 12 . Use enzymemodifying drug , include strong inhibitor cytochrome P450 ( CYP ) enzymes ( cimetidine , fluoxetine , quinidine , erythromycin , ciprofloxacin , fluconazole , ketoconazole , diltiazem HIV antiviral ) strong inducer CYP enzyme ( barbiturate , carbamazepine , glucocorticoid , phenytoin , rifampin St John 's Wort ) , previous 28 day day 1 study 13 . Use antihistaminic medication previous 7 day day 1 study 14 . Any history tuberculosis and/or prophylaxis tuberculosis 15 . Positive urine screen ethanol and/or drug abuse 16 . Positive result HIV , HBsAg antiHCV test 17 . Females pregnant accord positive serum pregnancy test 18 . Volunteers take Investigational Product ( another clinical trial ) donate 50 mL blood previous 28 day day 1 study 19 . Donation 500 mL blood ( Canadian Blood Services , HemaQuebec , clinical study , etc . ) previous 56 day day 1 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>